This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.
This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.
This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
In development [GID-NG10009] Expected publication date: 03 October 2018
In development [GID-NG10145] Expected publication date: 19 January 2022
In development [GID-NG10046] Expected publication date: 22 January 2020
In development [GID-NG10113] Expected publication date: 12 May 2021
In development [GID-TA10296] Expected publication date: 09 October 2019
In development [GID-TA10333] Expected publication date: 09 October 2019
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema
Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia
Evidence-based recommendations on aflibercept (Eylea) for treating diabetic macular oedema
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)
Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults